pharmanewsdaily
1509 posts
FDA approves Merck’s Keytruda in combination with chemotherapy for advanced lung cancer treatment
The US Food and Drug Administration (FDA) has granted approval to Merck’s cancer immunotherapy, Keytruda (pembrolizumab), in combination…
May 14, 2017
WHO announces first malaria vaccine trials in Ghana, Kenya, and Malawi
The World Health Organization (WHO) has announced a pivotal step in global health: the initiation of the world’s…
April 25, 2017
FDA approves Genentech’s lucentis for comprehensive diabetic retinopathy treatment
Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration (FDA)…
April 23, 2017
India’s CDSCO grants APAC Biotech license for immuno-oncology drug Apceden
The Central Drugs Standard Control Organization (CDSCO), India’s regulatory authority, has granted a commercial license to APAC Biotech…
April 16, 2017
FDA approves Neurocrine Biosciences’ Ingrezza for tardive dyskinesia
Neurocrine Biosciences has achieved a major milestone with the U.S. Food and Drug Administration (FDA) approving its medication,…
April 15, 2017
FDA approves Genentech’s Ocrevus for multiple sclerosis treatment
In a landmark decision, the US Food and Drug Administration (FDA) has granted approval to Genentech, a subsidiary…
April 2, 2017
Sanofi and Regeneron’s Dupixent receives FDA approval for atopic dermatitis treatment
Sanofi and Regeneron Pharmaceuticals have announced a significant advancement in dermatological care with the U.S. Food and Drug…
April 2, 2017
Lilly’s breast cancer drug abemaciclib shows promising results in phase 3 trial
Indianapolis-based pharmaceutical giant Lilly has announced positive outcomes from its phase 3 clinical trial, MONARCH 2, involving its…
March 22, 2017
Bayer and Janssen’s Xarelto shows promising results in reducing blood clot recurrence
Bayer AG and Janssen Pharmaceuticals, two giants in the pharmaceutical industry, have announced significant findings from their EINSTEIN…
March 19, 2017
AstraZeneca’s Lynparza shows promising results in phase 3 ovarian cancer trial
AstraZeneca has reported significant findings from its phase 3 trial, SOLO-2, for its ovarian cancer drug Lynparza (olaparib),…
March 18, 2017